On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use had adopted a positive opinion recommending a variation to the conditional marketing authorization to include a 50 ﾵg two-dose series of Spikevax, the Company’s vaccine against COVID-19, in children ages 6-11 years.

Following the CHMP’s positive opinion, the European Commission made an authorization decision on the use of Spikevax in children ages 6-11 years.